Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

QDEL vs DBVT vs HOLX vs ALKS vs BDX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
QDEL
QuidelOrtho Corporation

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$733M
5Y Perf.-93.8%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-58.8%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+42.6%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+116.4%
BDX
Becton, Dickinson and Company

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$55.53B
5Y Perf.+3.0%

QDEL vs DBVT vs HOLX vs ALKS vs BDX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
QDEL logoQDEL
DBVT logoDBVT
HOLX logoHOLX
ALKS logoALKS
BDX logoBDX
IndustryMedical - Instruments & SuppliesBiotechnologyMedical - Instruments & SuppliesBiotechnologyMedical - Instruments & Supplies
Market Cap$733M$1712.35T$16.97B$5.90B$55.53B
Revenue (TTM)$2.66B$0.00$4.13B$1.56B$21.36B
Net Income (TTM)$-1.21B$-168M$544M$153M$1.14B
Gross Margin56.6%52.8%65.4%46.5%
Operating Margin-37.0%17.5%12.3%10.6%
Forward P/E6.4x17.2x24.8x12.3x
Total Debt$2.80B$22M$2.63B$70M$19.18B
Cash & Equiv.$170M$194M$1.96B$1.12B$851M

QDEL vs DBVT vs HOLX vs ALKS vs BDXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

QDEL
DBVT
HOLX
ALKS
BDX
StockMay 20May 26Return
QuidelOrtho Corpora… (QDEL)1006.2-93.8%
DBV Technologies S.… (DBVT)10041.2-58.8%
Hologic, Inc. (HOLX)100142.6+42.6%
Alkermes plc (ALKS)100216.4+116.4%
Becton, Dickinson a… (BDX)100103.0+3.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: QDEL vs DBVT vs HOLX vs ALKS vs BDX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HOLX leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Becton, Dickinson and Company is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. QDEL and DBVT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
QDEL
QuidelOrtho Corporation
The Value Play

QDEL ranks third and is worth considering specifically for value.

  • Lower P/E (6.4x vs 12.3x)
Best for: value
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the clearest fit if your priority is momentum.

  • +110.4% vs QDEL's -58.3%
Best for: momentum
HOLX
Hologic, Inc.
The Long-Run Compounder

HOLX carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • 124.3% 10Y total return vs BDX's 80.2%
  • Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
  • Beta 0.41, current ratio 3.75x
  • 13.2% margin vs QDEL's -45.6%
Best for: long-term compounding and sleep-well-at-night
ALKS
Alkermes plc
The Quality Angle

Among these 5 stocks, ALKS doesn't own a clear edge in any measured category.

Best for: healthcare exposure
BDX
Becton, Dickinson and Company
The Income Pick

BDX is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.

  • Dividend streak 1 yrs, beta 0.66, yield 2.7%
  • Rev growth 8.2%, EPS growth -0.5%, 3Y rev CAGR 5.0%
  • 8.2% revenue growth vs DBVT's -100.0%
  • 2.7% yield; 1-year raise streak; the other 4 pay no meaningful dividend
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthBDX logoBDX8.2% revenue growth vs DBVT's -100.0%
ValueQDEL logoQDELLower P/E (6.4x vs 12.3x)
Quality / MarginsHOLX logoHOLX13.2% margin vs QDEL's -45.6%
Stability / SafetyHOLX logoHOLXBeta 0.41 vs QDEL's 2.59, lower leverage
DividendsBDX logoBDX2.7% yield; 1-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs QDEL's -58.3%
Efficiency (ROA)HOLX logoHOLX6.1% ROA vs DBVT's -89.0%

QDEL vs DBVT vs HOLX vs ALKS vs BDX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

QDELQuidelOrtho Corporation
FY 2023
Other
100.0%$483M
DBVTDBV Technologies S.A.

Segment breakdown not available.

HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
BDXBecton, Dickinson and Company
FY 2025
Medical
52.5%$11.5B
Interventional
23.9%$5.2B
Life Sciences
23.7%$5.2B

QDEL vs DBVT vs HOLX vs ALKS vs BDX — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGBDX

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 3 of 6 comparable metrics.

BDX and DBVT operate at a comparable scale, with $21.4B and $0 in trailing revenue. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to QDEL's -45.6%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricQDEL logoQDELQuidelOrtho Corpo…DBVT logoDBVTDBV Technologies …HOLX logoHOLXHologic, Inc.ALKS logoALKSAlkermes plcBDX logoBDXBecton, Dickinson…
RevenueTrailing 12 months$2.7B$0$4.1B$1.6B$21.4B
EBITDAEarnings before interest/tax-$649M-$112M$974M$212M$4.2B
Net IncomeAfter-tax profit-$1.2B-$168M$544M$153M$1.1B
Free Cash FlowCash after capex-$75M-$151M$1000M$392M$3.1B
Gross MarginGross profit ÷ Revenue+56.6%+52.8%+65.4%+46.5%
Operating MarginEBIT ÷ Revenue-37.0%+17.5%+12.3%+10.6%
Net MarginNet income ÷ Revenue-45.6%+13.2%+9.8%+5.3%
FCF MarginFCF ÷ Revenue-2.8%+24.2%+25.1%+14.7%
Rev. Growth (YoY)Latest quarter vs prior year-10.5%+2.5%+28.2%-10.6%
EPS Growth (YoY)Latest quarter vs prior year-6.1%+91.5%-9.2%-4.1%-2.0%
ALKS leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

QDEL leads this category, winning 3 of 6 comparable metrics.

At 24.8x trailing earnings, ALKS trades at a 19% valuation discount to HOLX's 30.5x P/E. On an enterprise value basis, BDX's 14.7x EV/EBITDA is more attractive than HOLX's 17.4x.

MetricQDEL logoQDELQuidelOrtho Corpo…DBVT logoDBVTDBV Technologies …HOLX logoHOLXHologic, Inc.ALKS logoALKSAlkermes plcBDX logoBDXBecton, Dickinson…
Market CapShares × price$733M$1712.35T$17.0B$5.9B$55.5B
Enterprise ValueMkt cap + debt − cash$3.4B$1712.35T$17.6B$4.9B$73.9B
Trailing P/EPrice ÷ TTM EPS-0.65x-0.76x30.53x24.76x26.29x
Forward P/EPrice ÷ next-FY EPS est.6.45x17.21x12.27x
PEG RatioP/E ÷ EPS growth rate1.59x
EV / EBITDAEnterprise value multiple17.39x17.25x14.65x
Price / SalesMarket cap ÷ Revenue0.27x4.14x4.00x2.54x
Price / BookPrice ÷ Book value/share0.38x0.66x3.43x3.28x1.73x
Price / FCFMarket cap ÷ FCF18.44x12.28x20.80x
QDEL leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 6 of 9 comparable metrics.

HOLX delivers a 11.0% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to QDEL's 1.46x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricQDEL logoQDELQuidelOrtho Corpo…DBVT logoDBVTDBV Technologies …HOLX logoHOLXHologic, Inc.ALKS logoALKSAlkermes plcBDX logoBDXBecton, Dickinson…
ROE (TTM)Return on equity-56.3%-130.2%+11.0%+8.8%+4.5%
ROA (TTM)Return on assets-20.7%-89.0%+6.1%+5.4%+2.1%
ROICReturn on invested capital-13.6%+9.4%+18.9%+4.3%
ROCEReturn on capital employed-18.0%-145.7%+8.8%+14.2%+5.4%
Piotroski ScoreFundamental quality 0–964777
Debt / EquityFinancial leverage1.46x0.13x0.52x0.04x0.76x
Net DebtTotal debt minus cash$2.6B-$172M$667M-$1.0B$18.3B
Cash & Equiv.Liquid assets$170M$194M$2.0B$1.1B$851M
Total DebtShort + long-term debt$2.8B$22M$2.6B$70M$19.2B
Interest CoverageEBIT ÷ Interest expense-5.18x-189.82x8.00x32.30x4.09x
ALKS leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DBVT leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $891 for QDEL. Over the past 12 months, DBVT leads with a +110.4% total return vs QDEL's -58.3%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs QDEL's -50.4% — a key indicator of consistent wealth creation.

MetricQDEL logoQDELQuidelOrtho Corpo…DBVT logoDBVTDBV Technologies …HOLX logoHOLXHologic, Inc.ALKS logoALKSAlkermes plcBDX logoBDXBecton, Dickinson…
YTD ReturnYear-to-date-62.6%+4.9%+1.9%+25.3%+0.7%
1-Year ReturnPast 12 months-58.3%+110.4%+37.1%+16.5%+51.8%
3-Year ReturnCumulative with dividends-87.8%+19.7%-8.5%+14.5%+5.0%
5-Year ReturnCumulative with dividends-91.1%-69.1%+15.8%+60.9%+16.9%
10-Year ReturnCumulative with dividends-34.9%-87.0%+124.3%-11.0%+80.2%
CAGR (3Y)Annualised 3-year return-50.4%+6.2%-2.9%+4.6%+1.6%
DBVT leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

HOLX leads this category, winning 2 of 2 comparable metrics.

HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than QDEL's 2.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs QDEL's 27.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricQDEL logoQDELQuidelOrtho Corpo…DBVT logoDBVTDBV Technologies …HOLX logoHOLXHologic, Inc.ALKS logoALKSAlkermes plcBDX logoBDXBecton, Dickinson…
Beta (5Y)Sensitivity to S&P 5002.59x1.26x0.41x1.06x0.66x
52-Week HighHighest price in past year$38.99$26.18$76.04$36.60$205.52
52-Week LowLowest price in past year$10.22$7.53$52.81$25.17$100.31
% of 52W HighCurrent price vs 52-week peak+27.6%+76.3%+100.0%+96.7%+74.6%
RSI (14)Momentum oscillator 0–10035.248.169.160.232.2
Avg Volume (50D)Average daily shares traded2.2M252K10.0M2.3M2.5M
HOLX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

BDX leads this category, winning 1 of 1 comparable metric.

Analyst consensus: QDEL as "Buy", DBVT as "Buy", HOLX as "Hold", ALKS as "Buy", BDX as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 3.9% for HOLX (target: $79). BDX is the only dividend payer here at 2.72% yield — a key consideration for income-focused portfolios.

MetricQDEL logoQDELQuidelOrtho Corpo…DBVT logoDBVTDBV Technologies …HOLX logoHOLXHologic, Inc.ALKS logoALKSAlkermes plcBDX logoBDXBecton, Dickinson…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuyBuy
Price TargetConsensus 12-month target$17.00$46.33$79.00$44.00$172.85
# AnalystsCovering analysts1515422833
Dividend YieldAnnual dividend ÷ price+2.7%
Dividend StreakConsecutive years of raises0001
Dividend / ShareAnnual DPS$4.17
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+4.4%+0.5%+1.8%
BDX leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). QDEL leads in 1 (Valuation Metrics).

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

QDEL vs DBVT vs HOLX vs ALKS vs BDX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is QDEL or DBVT or HOLX or ALKS or BDX a better buy right now?

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate QuidelOrtho Corporation (QDEL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — QDEL or DBVT or HOLX or ALKS or BDX?

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus Hologic, Inc. at 30. 5x. On forward P/E, QuidelOrtho Corporation is actually cheaper at 6. 4x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — QDEL or DBVT or HOLX or ALKS or BDX?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -91. 1% for QuidelOrtho Corporation (QDEL). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — QDEL or DBVT or HOLX or ALKS or BDX?

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus QuidelOrtho Corporation's 2. 59β — meaning QDEL is approximately 530% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — QDEL or DBVT or HOLX or ALKS or BDX?

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: QuidelOrtho Corporation grew EPS 45. 4% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — QDEL or DBVT or HOLX or ALKS or BDX?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -41. 5% for QuidelOrtho Corporation — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -33. 7% for QDEL. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is QDEL or DBVT or HOLX or ALKS or BDX more undervalued right now?

On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6.

4x forward P/E versus 17. 2x for Hologic, Inc. — 10. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — QDEL or DBVT or HOLX or ALKS or BDX?

In this comparison, BDX (2.

7% yield) pays a dividend. QDEL, DBVT, HOLX, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is QDEL or DBVT or HOLX or ALKS or BDX better for a retirement portfolio?

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 7% yield). QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BDX: +80. 2%, QDEL: -34. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between QDEL and DBVT and HOLX and ALKS and BDX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

BDX pays a dividend while QDEL, DBVT, HOLX, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

QDEL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 33%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

BDX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.0%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.